ENU 200 is being developed as a repurposed, orally deliverable antiviral drug by Ennaid Therapeutics, for the treatment of asymptomatic, mild to moderate COVID-2019 infections. The patent-pending drug, which was earlier approved against other indications, displays antiviral activity against two SARS-CoV-2 proteins, S glycoprotein and Mpro. S glycoprotein of covid virus is a class I viral fusion protein situated on the outer envelope of the virion, which facilitates host cell attachment by recognition of host cell receptors, along with a mediation of host cell membrane and viral membrane fusion during infection. Ennaid's in silico platform proposes that ENU 200 matches the receptor binding domain (RDB) by simultaneously blocking the key residues for binding to ACE2, (Gln493 and Asn501). ENU 200 also blocks CoV main protease (Mpro), which is responsible for CoV replication, and also for conversion of the polypeptide into functional proteins. Data has revealed Mpros as being largely conserved structures. This simultaneous dual blockage, the company believes, will pave the way for expanding treatment landscape for COVID-2019 and other coronaviruses, on account of an enhanced antiviral activity. In vitro and in vivo studies have validated that ENU 200 inhibits viral protease in a different viral infection, and has a good safety profile. Preclinical development is underway in the US.
Ennaid Therapeutics intends to utilise the US FDA's emergency/compassionate use regulatory pathway, or 505(b)(2) application process for ENU 200.
In April 2020, Ennaid Therapeutics reported that it has patent pending for ENU 200  .